2026-05-17T01:41:15Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/67452024-09-27T08:55:58Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605col_20.500.12105_19607
Repisalud author Baldan-Martin, Montserrat author Mourino-Alvarez, Laura author Gonzalez-Calero, Laura author Moreno-Luna, Rafael author Sastre-Oliva, Tamara author Ruiz-Hurtado, Gema author Segura, Julian author Lopez, Juan Antonio author Vazquez, Jesus author Vivanco, Fernando author Alvarez-Llamas, Gloria author Ruilope, Luis M author de la Cuesta, Fernando author Barderas, Maria G funder Instituto de Salud Carlos III funder Fundación Conchita Rábago de Jiménez Díaz funder Fundación SENEFRO funder Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) funder Redes Temáticas de Investigación Cooperativa en Salud (RETICS) (España) 2018-11-30T09:10:06Z 2018-11-30T09:10:06Z 2016 Hypertension. 2016 Jul;68(1):157-66. 10.1161/HYPERTENSIONAHA.116.07412 1524-4563 0194-911X Hypertension (Dallas, Tex. : 1979) 27217411 http://hdl.handle.net/20.500.12105/6745 Albuminuria is a risk factor strongly associated with cardiovascular disease, the first cause of death in the general population. It is well established that renin-angiotensin system suppressors prevent the development of new-onset albuminuria in naïf hypertensive patients and diminish its excretion, but we cannot forget the percentage of hypertensive patients who develop de novo albuminuria. Here, we applied multiple proteomic strategy with the purpose to elucidate specific molecular pathways involved in the pathogenesis and provide predictors and chronic organ damage indicators. Briefly, 1143 patients were followed up for a minimum period of 3 years. One hundred and twenty-nine hypertensive patients chronically renin-angiotensin system suppressed were recruited, classified in 3 different groups depending on their albuminuria levels (normoalbuminuria, de novo albuminuria, and sustained albuminuria), and investigated by multiple proteomic strategies. Our strategy allowed us to perform one of the deepest plasma proteomic analysis to date, which has shown 2 proteomic signatures: (1) with predictive value of de novo albuminuria and (2) sustained albuminuria indicator proteins. These proteins are involved in inflammation, immune as well as in the proteasome activation occurring in situations of endoplasmic reticulum stress. Furthermore, these results open the possibility of a future strategy based on anti-immune therapy to treat hypertension which could help to prevent the development of albuminuria and, hence, the progression of kidney damage. eng albuminuria cause of death hypertension immune system renin–angiotensin system Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators journal article Tk9OLUVYQ0xVU0lWRSBESVNUUklCVVRJT04gTElDRU5TRQoKQnkgc2lnbmluZyBhbmQgc3VibWl0dGluZyB0aGlzIGxpY2Vuc2UsIHlvdSAodGhlIGF1dGhvcihzKSBvciBjb3B5cmlnaHQgb3duZXIpCmdyYW50IHRvIFJFUElTQUxVRCB0aGUgbm9uLWV4Y2x1c2l2ZSByaWdodCB0byByZXByb2R1Y2UsIHRyYW5zbGF0ZSAoYXMgZGVmaW5lZApiZWxvdyksIGFuZC9vciBkaXN0cmlidXRlIHlvdXIgc3VibWlzc2lvbiAoaW5jbHVkaW5nIHRoZSBhYnN0cmFjdCkgd29ybGR3aWRlCmluIHByaW50IGFuZCBlbGVjdHJvbmljIGZvcm1hdCBhbmQgaW4gYW55IG1lZGl1bSwgaW5jbHVkaW5nIGJ1dCBub3QgbGltaXRlZAp0byBhdWRpbyBvciB2aWRlby4KCllvdSBhZ3JlZSB0aGF0IFJFUElTQUxVRCBtYXkgY29udmVydCB0aGUgc3VibWlzc2lvbiwgd2l0aG91dCBjaGFuZ2luZyB0aGUgCmNvbnRlbnQsIHRvIGFueSBtZWRpdW0gb3IgZm9ybWF0IGZvciB0aGUgcHVycG9zZSBvZiBwcmVzZXJ2YXRpb24uCllvdSBhbHNvIGFncmVlIHRoYXQgUkVQSVNBTFVEIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24KZm9yIHB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCiAKWW91IGRlY2xhcmUgdGhhdCB0aGUgc3VibWlzc2lvbiBpcyB5b3VyIG9yaWdpbmFsIHdvcmssIGFuZCB0aGF0IHlvdSBoYXZlIHRoZQpyaWdodCB0byBncmFudCB0aGUgcmlnaHRzIGNvbnRhaW5lZCBpbiB0aGlzIGxpY2Vuc2UuIFlvdSBhbHNvIGRlY2xhcmUgdGhhdCAKeW91ciBzdWJtaXNzaW9uIGRvZXMgbm90IGluZnJpbmdlIHVwb24gYW55b25lJ3MgY29weXJpZ2h0IHRvIHRoZSBiZXN0IG9mIHlvdXIgCmtub3dsZWRnZS4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LCB5b3UKZGVjbGFyZSB0aGF0IHlvdSBoYXZlIG9idGFpbmVkIHRoZSB1bnJlc3RyaWN0ZWQgcGVybWlzc2lvbiBvZiB0aGUgY29weXJpZ2h0IApvd25lciB0byBncmFudCBSRVBJU0FMVUQgdGhlIHJpZ2h0cyByZXF1aXJlZCBieSB0aGlzIGxpY2Vuc2UsIGFuZCB0aGF0IHN1Y2ggCnRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkIHdpdGhpbiB0aGUgCnRleHQgb3IgY29udGVudCBvZiB0aGUgc3VibWlzc2lvbi4KCklmIHRoZSBzdWJtaXNzaW9uIGlzIGJhc2VkIHVwb24gd29yayB0aGF0IGhhcyBiZWVuIHNwb25zb3JlZCBvciBzdXBwb3J0ZWQgYnkgCmFuIGFnZW5jeSBvciBvcmdhbml6YXRpb24gb3RoZXIgdGhhbiBSRVBJU0FMVUQsIHlvdSBkZWNsYXJlIHRoYXQgeW91IGhhdmUgCmZ1bGZpbGxlZCBhbnkgcmlnaHQgb2YgcmV2aWV3IG9yIG90aGVyIG9ibGlnYXRpb25zIHJlcXVpcmVkIGJ5IHN1Y2ggY29udHJhY3QgCm9yIGFncmVlbWVudC4KClJFUElTQUxVRCB3aWxsIGNsZWFybHkgaWRlbnRpZnkgeW91ciBuYW1lKHMpIGFzIHRoZSBhdXRob3Iocykgb3Igb3duZXIocykgb2YgCnRoZSBzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IAp0aGlzIGxpY2Vuc2UsIHRvIHlvdXIgc3VibWlzc2lvbi4gCg== URL https://repisalud.isciii.es/bitstreams/dfcf9530-d515-4cf5-9594-d2bf36655748/download File MD5 f7502e94afe5b35cd6f0cc18b81b3d49 675334 application/pdf PlasmaMolecularSignaturesHypertensive_2016.pdf URL https://repisalud.isciii.es/bitstreams/6f9a0c4c-209b-4363-9d5c-1b792d267271/download File MD5 50fbe1b2ee7c86381465460698a0bbbb 139779 application/pdf HyperSuppl2016.pdf URL https://repisalud.isciii.es/bitstreams/7890556b-8fdf-4518-ab49-feaa949ba83b/download File MD5 1c9ecdf0098d7bb7c90f676396ad7f2f 46175 text/plain PlasmaMolecularSignaturesHypertensive_2016.pdf.txt URL https://repisalud.isciii.es/bitstreams/439cec94-4590-459b-9ac7-f24de5490c9b/download File MD5 3dc052b0777ae3deaec9a19ee3ddf077 9805 text/plain HyperSuppl2016.pdf.txt